Stella Pharma Corporation

Tokyo Stock Exchange 4888.T

Stella Pharma Corporation Free Cash Flow Yield on January 14, 2025: -5.47%

Stella Pharma Corporation Free Cash Flow Yield is -5.47% on January 14, 2025, a 10.62% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.
  • Stella Pharma Corporation 52-week high Free Cash Flow Yield is -4.36% on October 01, 2024, which is 20.37% above the current Free Cash Flow Yield.
  • Stella Pharma Corporation 52-week low Free Cash Flow Yield is -7.60% on August 05, 2024, which is -38.94% below the current Free Cash Flow Yield.
  • Stella Pharma Corporation average Free Cash Flow Yield for the last 52 weeks is -5.22%.
Key data
Date Free Cash Flow Yield Market Value Added (MVA) Price to Book Ratio (P/B) Price to Earnings Ratio (P/E)
Market news
Tokyo Stock Exchange: 4888.T

Stella Pharma Corporation

CEO Mr. Koki Uehara
IPO Date April 22, 2021
Location Japan
Headquarters ORIX Kouraibashi Building
Employees 44
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Stella Pharma Corporation engages in the research, development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its product includes SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma and meningioma, and malignant melanoma and angiosarcoma. The company was incorporated in 2007 and is headquartered in Osaka, Japan.

StockViz Staff

January 15, 2025

Any question? Send us an email